Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

PHASE4CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Stable AnginaCoronary Disease
Interventions
DRUG

Nicorandil

The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.

DRUG

Standard Treatment

The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.

Trial Locations (1)

Unknown

For Locations in, Beijing

All Listed Sponsors
collaborator

Merck Serono Co., Ltd., China

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01396395 - Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina | Biotech Hunter | Biotech Hunter